{"id":"W2528228811","doi":"10.1056/nejmoa1611310","title":"Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer","year":2016,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2458,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University Health Centre; BC Cancer Agency; Princess Margaret Cancer Centre; University Health Network","funders":"Cilag; Genentech; PharmaMar; Medac; University College London; Clovis Oncology; Array BioPharma; USC Norris Comprehensive Cancer Center; Massachusetts Medical Society; Ohio State University; Teva Pharmaceutical Industries; Amgen; Pfizer; Myriad Genetics; AstraZeneca; Eli Lilly and Company; Mateon Therapeutics; GlaxoSmithKline","keywords":"Ovarian cancer; Platinum; Oncology; Maintenance therapy; Medicine; Internal medicine; Cancer; Chemotherapy; Chemistry; Biochemistry","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03768055663310116,"score_gpt":0.3259895611761575,"score_spread":0.2883090045430563,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}